HDII (Hypertension Diagnostics) YoY EBITDA Growth: 0.00% (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hypertension Diagnostics YoY EBITDA Growth?

Hypertension Diagnostics HDII -99.00% YoY EBITDA Growth is 0.00% as of Sep. 2019.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Hypertension Diagnostics's YoY EBITDA Growth for the quarter that ended in Sep. 2019 was 0.00%.

Hypertension Diagnostics's EBITDA per Share for the three months ended in Sep. 2019 was $0.00.

Hypertension Diagnostics YoY EBITDA Growth Related Terms

Hypertension Diagnostics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Hypertension Diagnostics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hypertension Diagnostics YoY EBITDA Growth Chart

Hypertension Diagnostics Annual Data
Trend Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Dec16 Dec17 Dec18
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -333.33 -228.57 65.22 62.50 133.33

Hypertension Diagnostics Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Dec16 Dec17 Dec18 Mar19 Jun19 Sep19
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.00 100.00 100.00 0.00 0.00

Hypertension Diagnostics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Hypertension Diagnostics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2018 is calculated as:

YoY EBITDA Growth (A: Dec. 2018 )
=(EBITDA per Share (A: Dec. 2018 )-EBITDA per Share (A: Dec. 2017 ))/ | EBITDA per Share (A: Dec. 2017 ) |
=(0.001--0.003)/ | -0.003 |
=133.33 %

Hypertension Diagnostics's YoY EBITDA Growth for the quarter that ended in Sep. 2019 is calculated as:

YoY EBITDA Growth (Q: Sep. 2019 )
=(EBITDA per Share (Q: Sep. 2019 )-EBITDA per Share (Q: Dec. 2017 )) / | EBITDA per Share (Q: Dec. 2017 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
Hypertension Diagnostics (HDII) has a YoY EBITDA Growth of 0.00% as of Sep. 2019. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Hypertension Diagnostics and its competitors.
Is Hypertension Diagnostics' YoY EBITDA Growth too high?
Hypertension Diagnostics' current YoY EBITDA Growth is 0.00%.
How does Hypertension Diagnostics' YoY EBITDA Growth compare to ESTRF and OCLN?
Hypertension Diagnostics' YoY EBITDA Growth of 0.00% can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Diversified Financial Services company?
A good YoY EBITDA Growth depends on the Diversified Financial Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Hypertension Diagnostics and its competitors. Hypertension Diagnostics's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypertension Diagnostics stock overvalued right now?
Hypertension Diagnostics (HDII) has a current YoY EBITDA Growth of 0.00%. The current YoY EBITDA Growth is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Hypertension Diagnostics (HDII), the current YoY EBITDA Growth is 0.00% as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hypertension Diagnostics Business Description

Address 550 Highway 7 Unit 316, Ontario, ON, CAN, L4B324
Hypertension Diagnostics Inc is a shell company.